The cerebral vasculature, with its extensive network of arteries, veins, capillaries, and perivascular compartments, constitutes a substantial component of the brain and provides indispensable support to brain cells. In fact, the proper functioning of neurons and neuronal circuits is strongly dependent on continuous and sufficient oxygen and glucose supply from the blood, and in general, a healthy brain relies on healthy cerebral blood vessels. The cerebral vasculature also presents unique properties, especially the blood-brain barrier (BBB), that prevent solutes and cells in the blood from non-selectively crossing into the extracellular fluid and the parenchyma of the central nervous system where neurons and other brain cells reside. Moreover, recent preclinical data support a critical role of the paravascular and the intramural periarterial compartments as drainage systems of the brain, while clinical studies investigate MRI-visible perivascular spaces (PVS) in the context of neurodegeneration. These findings have significant implications for a better understanding of the pathogenesis and development of therapeutic approaches in several neurological disorders, especially neurodegenerative diseases.The purpose of this Research Topic was to increase knowledge of the role played by the cerebral vasculature in neurodegenerative diseases, such as cerebral small vessel disease, vascular cognitive impairment, Alzheimer's disease (AD), and dementia. In recent years, novel neuroimaging methods and technological advancements enabled improvements in the visualization and quantification of the cerebral vasculature and its multiple components, including PVS and BBB. From a clinical point of view, these advancements are important for optimizing current diagnostic frameworks, identifying early biomarkers, and developing novel therapeutic strategies for neurodegenerative disease utilizing the cerebral vasculature.In their review article, Lynch et al. give an overview of the current knowledge and gaps in understanding the contribution of PVS to AD. In particular, after describing AD, established AD biomarkers, and the glymphatic system, they summarized results from studies investigating the potential use of MRI-visible PVS as a non-invasive imaging biomarker in AD as well as the relationship between MRI-visible PVS, amyloid-beta, and tau. The review highlighted the need for further studies investigating these relationships, both cross-sectionally and longitudinally, to improve our comprehension of the role of PVS in AD in humans.Another review article by Pham et al. summarized the recent developments in PVS segmentation and quantification on MRI. They described the current approaches for evaluating PVS in humans, including visual rating scales, segmentation, and machine learning techniques, and made comparisons between these techniques when feasible. This review also summarized the current challenges in PVS segmentation and proposed potential solutions.In the study by Moses et al., the authors evaluated the utility of PVS burden assessed on MRI as a biomarker in patients with behavioral variant frontotemporal dementia. They used an automated technique to segment PVS on T1-weighted images. In their exploratory study with 12 patients, they found a trend toward an association between PVS burden and disease progression, as well as between the measures of t-tau and neurofilament light chain in the cerebrospinal fluid and PVS burden longitudinally. Their study suggests a potential involvement of PVS in neurodegenerative changes observed in these patients. Further studies are needed in order to understand the possible use of PVS as a biomarker for disease progression and/or as a therapeutic target in frontotemporal dementia.The glymphatic system clearance activity is based on aquaporin-4 (AQP4) water channels expressed on the end-feet of astrocytes lining on the parenchymal side of the perivascular compartment. The study by Wang et al. in rats with painful diabetic neuropathy manifesting mechanical allodynia and impairment in the glymphatic system showed that β-Hydroxybutyrate is able to restore AQP4 polarity in the spinal glymphatic system leading to enhanced glymphatic clearance and reduced mechanical allodynia compared with untreated animals. These encouraging results provide a promising therapeutic strategy for diabetic neuropathy.The BBB is a vascular component mediating the interaction between the blood, PVS, and the brain. In their review, Yuan, Sun, et al. focused on brain endothelial cells of the BBB, and their role in the pathophysiology of neurodegenerative disorders. In particular, the authors described the studies investigating how active signals released and received by brain endothelial cells may contribute to the pathogenesis of neurodegeneration, both facilitating the accumulation and deposition of pathological proteins and through pathways independent of pathological proteins, such as neuroinflammation. A better understanding of the molecular mechanisms underlying BBB and brain endothelial cell dysfunction will be critical for the development of therapeutic strategies targeting the blood vessels.Another important component of the brain vasculature is represented by the vascular smooth muscle cells, which play a key role in cerebrovascular dynamics, enabling the appropriate provision of oxygen and nutrients to the brain. In their review, Hayes et al. described the role of vascular smooth muscle cells in the most common neurodegenerative disorders and what biological signaling pathways and physiological systems may contribute to their dysfunction. Moreover, they reviewed recent studies investigating cerebrovascular reactivity dysfunction and cerebral blood flow in patients with neurodegenerative and/or cerebrovascular pathologies and
Editorial29 September 2023
Editorial: Vascular and perivascular contributions to neurodegenerationAs blood-brain barrier (BBB) disruption emerges as a common problem in the early stages of neurodegenerative diseases, the crucial roles of barrier-type brain endothelial cells (BECs), the primary part of the BBB, have been reported in the pathophysiology of neurodegenerative diseases. The mechanisms of how early vascular dysfunction contributes to the progress of neurodegeneration are still unclear, and understanding BEC functions is a promising start. Our understanding of the BBB has gone through different stages, from a passive diffusion barrier to a mediator of central-peripheral interactions. BECs serve two seemingly paradoxical roles: as a barrier to protect the delicate brain from toxins and as an interface to constantly receive and release signals, thus maintaining and regulating the homeostasis of the brain. Most previous studies about neurodegenerative diseases focus on the loss of barrier functions, and far too little attention has been paid to the active regulations of BECs. In this review, we present the current evidence of BEC dysfunction in neurodegenerative diseases and explore how BEC signals participate in the pathogenesis of neurodegenerative diseases.
The glymphatic system is responsible for waste clearance in the brain. It is comprised of perivascular spaces (PVS) that surround penetrating blood vessels. These spaces are filled with cerebrospinal fluid and interstitial fluid, and can be seen with magnetic resonance imaging. Various algorithms have been developed to automatically label these spaces in MRI. This has enabled volumetric and morphological analyses of PVS in healthy and disease cohorts. However, there remain inconsistencies between PVS measures reported by different methods of automated segmentation. The present review emphasizes that importance of voxel-wise evaluation of model performance, mainly with the Sørensen Dice similarity coefficient. Conventional count correlations for model validation are inadequate if the goal is to assess volumetric or morphological measures of PVS. The downside of voxel-wise evaluation is that it requires manual segmentations that require large amounts of time to produce. One possible solution is to derive these semi-automatically. Additionally, recommendations are made to facilitate rigorous development and validation of automated PVS segmentation models. In the application of automated PVS segmentation tools, publication of image quality metrics, such as the contrast-to-noise ratio, alongside descriptive statistics of PVS volumes and counts will facilitate comparability between studies. Lastly, a head-to-head comparison between two algorithms, applied to two cohorts of astronauts reveals how results can differ substantially between techniques.
REVIEW
18 October 2022
Miranda Lynch, 4 more and Lucy Vivash
6 Authors
- ML
Miranda Lynch
Department of Neuroscience, Central Clinical School, Monash University, Australia
- WP
William Pham
Department of Neuroscience, Central Clinical School, Monash University, Australia
- BS
Benjamin Sinclair
Department of Neuroscience, Central Clinical School, Monash University, Australia
- TJ
Terence J. O’Brien
Department of Neuroscience, Central Clinical School, Monash University, Australia
- ML
Meng Law
Department of Neuroscience, Central Clinical School, Monash University, Australia
- LV
Lucy Vivash
Department of Neuroscience, Central Clinical School, Monash University, Australia
Alzheimer's disease (AD) is a highly damaging disease that affects one's cognition and memory and presents an increasing societal and economic burden globally. Considerable research has gone into understanding AD; however, there is still a lack of effective biomarkers that aid in early diagnosis and intervention. The recent discovery of the glymphatic system and associated Perivascular Spaces (PVS) has led to the theory that enlarged PVS (ePVS) may be an indicator of AD progression and act as an early diagnostic marker. Visible on Magnetic Resonance Imaging (MRI), PVS appear to enlarge when known biomarkers of AD, amyloid-β and tau, accumulate. The central goal of ePVS and AD research is to determine when ePVS occurs in AD progression and if ePVS are causal or epiphenomena. Furthermore, if ePVS are indeed causative, interventions promoting glymphatic clearance are an attractive target for research. However, it is necessary first to ascertain where on the pathological progression of AD ePVS occurs. This review aims to examine the knowledge gap that exists in understanding the contribution of ePVS to AD. It is essential to understand whether ePVS in the brain correlate with increased regional tau distribution and global or regional Amyloid-β distribution and to determine if these spaces increase proportionally over time as individuals experience neurodegeneration. This review demonstrates that ePVS are associated with reduced glymphatic clearance and that this reduced clearance is associated with an increase in amyloid-β. However, it is not yet understood if ePVS are the outcome or driver of protein accumulation. Further, it is not yet clear if ePVS volume and number change longitudinally. Ultimately, it is vital to determine early diagnostic criteria and early interventions for AD to ease the burden it presents to the world; ePVS may be able to fulfil this role and therefore merit further research.




